| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/17/2022 | 83.49% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 05/24/2022 | 83.49% | Goldman Sachs | $21 → $12 | Maintains | Buy |
| 03/31/2022 | 221.1% | Goldman Sachs | $31 → $21 | Maintains | Buy |
| 01/06/2022 | 205.81% | Morgan Stanley | $25 → $20 | Maintains | Overweight |
| 07/12/2021 | 282.26% | Morgan Stanley | → $25 | Initiates Coverage On | → Overweight |
| 07/12/2021 | 282.26% | B of A Securities | → $25 | Initiates Coverage On | → Buy |
| 07/12/2021 | 236.39% | JP Morgan | → $22 | Initiates Coverage On | → Overweight |
| 07/12/2021 | 358.72% | Goldman Sachs | → $30 | Initiates Coverage On | → Buy |
Lyell Immunopharma Questions & Answers
The latest price target for Lyell Immunopharma (NASDAQ: LYEL) was reported by HC Wainwright & Co. on October 17, 2022. The analyst firm set a price target for $12.00 expecting LYEL to rise to within 12 months (a possible 83.49% upside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for Lyell Immunopharma (NASDAQ: LYEL) was provided by HC Wainwright & Co., and Lyell Immunopharma initiated their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lyell Immunopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lyell Immunopharma was filed on October 17, 2022 so you should expect the next rating to be made available sometime around October 17, 2023.
While ratings are subjective and will change, the latest Lyell Immunopharma (LYEL) rating was a initiated with a price target of $0.00 to $12.00. The current price Lyell Immunopharma (LYEL) is trading at is $6.54, which is within the analyst's predicted range.